The overall scope of the study presents the benefits of an exploratory work at the development stage of a new drug-nebuliser combination product, aiming to identify the most suitable pair for the targeted delivery requirements.
The investigations revealed the potential efficacy of IFN-β in the treatment of IPF with the mesh nebulizer, demonstrating the higher efficiency of IFN-β delivered through the mesh nebulizer.
The breath-actuated function of the mesh nebuliser, AdheResp, allowed for a substantial reduction in fugitive aerosol emission, demonstrating the benefits of breath actuation to reduce risk to fugitive aerosol exposure during nebulisation treatment.
HCmed Innovations summarizes the development process of drug-nebulizer combination products, describing a roadmap from early development to commercialization.
This study aimed to evaluate two in-vitro test methods when assessing delivered dose for a breath-actuated mesh nebulizer, which only relies on a breathing simulator and the new method that incorporates a mixing inlet.